As filed with the Securities and Exchange Commission on August 29, 2006
Registration No. 333-
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
BIOMARIN PHARMACEUTICAL INC.
(Exact Name of Registrant as Specified in Its Charter)
| Delaware | 68-0397820 | |
|
(State or Other Jurisdiction of Incorporation or Organization) |
(I.R.S. Employer Identification No.) |
105 Digital Drive
Novato, California 94949
(Address of Principal Executive Offices)
Amended and Restated BioMarin Pharmaceutical Inc. 2006 Share Incentive Plan
BioMarin Pharmaceutical Inc. Amended and Restated 2006 Employee Stock
BioMarin Pharmaceutical Inc. 1997 Stock Plan
BioMarin Pharmaceutical Inc. 1998 Director Option Plan
(Full title of the Plans)
G. Eric Davis, Esq.
Vice President, General Counsel and Secretary
BioMarin Pharmaceutical Inc.
105 Digital Drive
Novato, California 94949
(Name and Address of Agent For Service)
(415) 506-6700
(Telephone Number, Including Area Code, of Agent for Service)
Copy to:
Thomas Pollock, Esq.
Paul, Hastings, Janofsky & Walker LLP
55 Second Street
San Francisco, California 94105-3441
(415) 856-7000
CALCULATION OF REGISTRATION FEE
| Title of Securities to be Registered |
Amount to be
Registered (1) |
Proposed
Maximum Offering Price Per Share |
Proposed
Maximum Aggregate Offering Price |
Amount of
Registration Fee |
|||||||||||
|
Under Amended and Restated BioMarin Pharmaceutical Inc. 2006 Share Incentive Plan: Common Stock, $0.001 par value |
15,000,000 | (2) | $ | 15.675 | (3) | $ | 235,125,000 | (3) | $ | 25,158.38 | (3) | ||||
|
Under BioMarin Pharmaceutical Inc. Amended and Restated 2006 Employee Stock Purchase Plan: Common Stock, $0.001 par value |
2,500,000 | (2) | $ | 15.675 | (3) | $ | 39,187,500 | (3) | $ | 4,193.06 | (3) | ||||
|
Under BioMarin Pharmaceutical Inc. 1997 Stock Plan: Common Stock, $0.001 par value |
1,664,775 | (2) | $ | 15.675 | (3) | $ | 26,095,348 | (3) | $ | 2,792.20 | (3) | ||||
|
Under BioMarin Pharmaceutical Inc. 1998 Director Option Plan: Common Stock, $0.001 par value |
135,000 | (2) | $ | 15.675 | (3) | $ | 2,116,125 | (3) | $ | 226.43 | (3) | ||||
| (1) | This Registration Statement shall also cover any additional shares of Common Stock which become issuable under the Amended and Restated BioMarin Pharmaceutical Inc. 2006 Share Incentive Plan, the BioMarin Pharmaceutical Inc. Amended and Restated 2006 Employee Stock Purchase Plan, the BioMarin Pharmaceutical Inc. 1997 Stock Plan or the BioMarin Pharmaceutical Inc. 1998 Director Option Plan by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the receipt of consideration which results in an increase in the number of the outstanding shares of BioMarin Pharmaceutical Inc. Common Stock. |
| (2) | Includes preferred share purchase rights, which are attached to the shares of Common Stock to be issued but do not trade separately from the shares of Common Stock until a triggering event. No additional offering price attaches to these rights. |
| (3) | Estimated solely for the purpose of calculating the amount of the registration fee in accordance with Rules 457(c) and (h) under the Securities Act of 1933, as amended, on the basis of the average of high and low sale prices for a share of common stock of BioMarin Pharmaceutical Inc. (BMRN) as reported on The NASDAQ Global Market on August 25, 2006. |
PART I
Item 2. Registrant Information and Employee Plan Annual Information.*
*Information required by Part I to be contained in the Section 10(a) prospectus is omitted from the Registration Statement in accordance with Rule
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The following documents are hereby incorporated into this Registration Statement and made a part hereof by this reference:
| (a) (1) | The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2005, as filed on March 7, 2006; | |
| (a) (2) | The Registrant’s Annual Report on Form 10-K/A for the fiscal year ended December 31, 2005, as filed on March 20, 2006; | |
| (b) (1) | The Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2006, as filed on May 4, 2006; | |
| (b) (2) | The Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2006, as filed on August 3, 2006; | |
| (b) (3) | The Registrant’s Current Report on Form 8-K, as filed on January 30, 2006; | |
| (b) (4) | The Registrant’s Current Report on Form 8-K, as filed on February 28, 2006; | |
| (b) (5) | The Registrant’s Current Report on Form 8-K, as filed on March 15, 2006; | |
| (b) (6) | The Registrant’s Current Report on Form 8-K, as filed on March 22, 2006; | |
| (b) (7) | The Registrant’s Current Report on Form 8-K, as filed on March 28, 2006; | |
| (b) (8) | The Registrant’s Current Report on Form 8-K, as filed on March 29, 2006; | |
| (b) (9) | The Registrant’s Current Report on Form 8-K, as filed on May 12, 2006; | |
| (b) (10) | The Registrant’s Current Report on Form 8-K, as filed on June 1, 2006; | |
| (b) (11) | The Registrant’s Current Report on Form 8-K, as filed on June 16, 2006; | |
| (b) (11) | The Registrant’s Current Report on Form 8-K, as filed on June 27, 2006; and | |
| (c) (1) | The description of the Registrant’s capital stock contained in the Registrant’s Registration Statement on Form S-3ASR, as filed on March 20, 2006. | |
In addition, all documents filed by the Registrant with the Securities and Exchange Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents with the Securities and Exchange Commission.
Item 4. Description of Securities.
Not applicable.
Item 5. Interests of Named Experts and Counsel.
Not applicable.
Item 6. Indemnification of Directors and Officers.
Reference is made to the Amended and Restated Certificate of Incorporation, including the Certificate of Correction to the Certificate of Amendment to the Amended and Restated Certificate of Incorporation, of the Registrant (together, the “Certificate”), the Amended and Restated Bylaws of the Registrant (the “Bylaws”); and Section 145 of the Delaware General Corporation Law; which, among other things, and subject to certain conditions, authorize the Registrant to indemnify, or indemnify by their terms, as the case may be, the directors and officers of the Registrant to the fullest extent permitted by the Delaware General Corporation Law, against certain liabilities and expenses incurred by such persons in connection with claims made by reason of their being such a director or officer.
The Registrant maintains directors’ and officers’ insurance providing indemnification against certain liabilities for certain of the Registrant’s directors and officers.
The indemnification provisions in the Registrant’s Certificate and Bylaws may be sufficiently broad to permit indemnification of the Registrant’s officers and directors for liabilities arising under the Act.
Reference is made to the following documents incorporated by reference into this Registration Statement regarding relevant indemnification provisions described above and elsewhere herein: (1) the Registrant’s Amended and Restated Certificate of Incorporation, filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 23, 2003; (2) the Registrant’s Corrected Certificate of Amendment to Amended and Restated Certificate of Incorporation, filed as Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 5, 2005; and (3) the Registrant’s Amended and Restated Bylaws, filed as Exhibit 3.1 to Registrant’s
Item 7. Exemption from Registration Claimed.
Not applicable.
Item 8. Exhibits.
| Exhibit |
Description |
|
| 4.1 | Amended and Restated Certificate of Incorporation (1) | |
| 4.2 | Corrected Certificate of Amendment of the Registrant’s Amended and Restated Certificate of Incorporation (2) | |
| 4.3 | Amended and Restated Bylaws (3) | |
| 4.4 | Amended and Restated BioMarin Pharmaceutical Inc. 2006 Share Incentive Plan (4) | |
| 4.5 | BioMarin Pharmaceutical Inc. Amended and Restated 2006 Employee Stock Purchase Plan (5) | |
| 4.6 | BioMarin Pharmaceutical Inc. 1997 Amended Stock Plan and Forms of Agreement (6) | |
| 4.7 | Amendment to BioMarin Pharmaceutical Inc. 1997 Stock Plan (7) | |
| 4.8 | Amendment No. 2 to BioMarin Pharmaceutical Inc. 1997 Stock Plan (8) | |
| 4.9 | BioMarin Pharmaceutical Inc. 1998 Director Option Plan (9) | |
| 4.10 | Amendment No. 1 to BioMarin Pharmaceutical Inc. 1998 Director Option Plan (10) | |
| 4.11 | Amendment No. 2 to BioMarin Pharmaceutical Inc. 1998 Director Option Plan (11) | |
| 4.12 | Amendment No. 3 to BioMarin Pharmaceutical Inc. 1998 Director Option Plan (12) | |
| 5.1 | Opinion of Paul, Hastings, Janofsky & Walker LLP * | |
| 23.1 | Consent of Paul, Hastings, Janofsky & Walker LLP (included with 5.1) * | |
| 23.2 | Consent of KPMG LLP, Independent Registered Public Accounting Firm for BioMarin Pharmaceutical Inc. * | |
| 23.3 | Consent of PricewaterhouseCoopers, LLP, Independent Registered Public Accounting Firm for BioMarin/Genzyme LLC * | |
| 24.1 | Power of Attorney (contained on the signature page) | |
| * | Filed herewith. |
| (1) | Incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 23, 2003 (SEC File No. 000-26727). |
| (2) | Incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 5, 2005 (SEC File No. 000-26727). |
| (3) | Incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 27, 2006 (SEC File No. 000-26727). |
| (4) | Incorporated by reference to Exhibit 99.1 of the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 16, 2006 (SEC File No. 000-26727). |
| (5) | Incorporated by reference to Exhibit 10.3 of the Registrant’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 3, 2006 (SEC File No. 000-26727). |
| (6) | Incorporated by reference to Exhibit 10.2 of the Registrant’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on May 4, 1999 (SEC File No. 333-77701). |
| (7) | Incorporated by reference to Exhibit 99.1 of the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 31, 2002 (SEC File No. 000-26727). |
| (8) | Incorporated by reference to Exhibit 10.1 of the Registrant’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 9, 2004 (SEC File No. 000-26727). |
| (9) | Incorporated by reference to Exhibit 10.3 of the Registrant’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on May 4, 1999 (SEC File No. 333-77701). |
| (10) | Incorporated by reference to Exhibit 10.1 of the Registrant’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 15, 2003 (SEC File No. 000-26727). |
| (11) | Incorporated by reference to Exhibit 10.1 of the Registrant’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2003 (SEC File No. 000-26727). |
| (12) |
Incorporated by reference to Exhibit 10.2 of the Registrant’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 9, 2004 (SEC File
|
Item 9. Undertakings.
| A. | Undertakings required by Item 512(a) of Regulation S-K. |
| (a) | The Registrant hereby undertakes: |
(1) To file, during any period in which offers or sales are being made, a post- effective amendment to this Registration Statement:
(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;
(ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities
offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and
(iii) To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;
Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.
(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment to this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(3) To remove from registration by means of a post-effective amendment any of the securities being registered that remain unsold at the termination of the offering.
(4) That, for the purpose of determining liability of the Registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities: The undersigned Registrant undertakes that in a primary offering of securities of the undersigned Registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned Registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:
(i) Any preliminary prospectus or prospectus of the undersigned Registrant relating to the offering required to be filed pursuant to Rule 424;
(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned Registrant or used or referred to by the undersigned Registrant;
(iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned Registrant or its securities provided by or on behalf of the undersigned Registrant; and
(iv) Any other communication that is an offer in the offering made by the undersigned Registrant to the purchaser.
| B. | Undertakings required by Item 512(b) of Regulation S-K. |
The Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
| C. | Undertakings required by Item 512(h) of Regulation S-K. |
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Novato, State of California, this 28th day of August, 2006.
| BIOMARIN PHARMACEUTICAL INC. | ||
| By: |
/s/ Jean-Jacques Bienaimé |
|
| Jean-Jacques Bienaimé | ||
| Chief Executive Officer and Director | ||
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each of the Registrant, and the undersigned directors and officers of the Registrant hereby constitute and appoint Jean-Jacques Bienaimé or G. Eric Davis as his true and lawful attorneys-in-fact and agents, for him or her and in his or her name, place and stead, in any and all capacities, with full power to act alone, to sign any and all amendments to this Registration Statement, and to file each such amendment to this Registration Statement, with all exhibits thereto, and any and all documents in connection therewith, with the Securities and Exchange Commission, hereby granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform any and all acts and things requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
|
Signature |
Title |
Date |
||
|
/s/ Jean-Jacques Bienaimé Jean-Jacques Bienaimé |
Chief Executive Officer and Director (Principal Executive Officer) |
August 28, 2006 | ||
|
/s/ Jeffrey H. Cooper Jeffrey H. Cooper |
Chief Financial Officer (Principal Financial and Accounting Officer) |
August 28, 2006 | ||
|
/s/ Elaine J. Heron Elaine J. Heron |
Director | August 28, 2006 | ||
|
/s/ Joseph Klein, III Joseph Klein, III |
Director | August 28, 2006 | ||
|
Signature |
Title |
Date | ||
|
/s/ Pierre Lapalme Pierre Lapalme |
Director | August 28, 2006 | ||
|
/s/ Alan Lewis Alan Lewis |
Director | August 28, 2006 | ||
EXHIBIT INDEX
| Exhibit |
Description |
|
| 4.1 | Amended and Restated Certificate of Incorporation (1) | |
| 4.2 | Corrected Certificate of Amendment of the Registrant’s Amended and Restated Certificate of Incorporation (2) | |
| 4.3 | Amended and Restated Bylaws (3) | |
| 4.4 | Amended and Restated BioMarin Pharmaceutical Inc. 2006 Share Incentive Plan (4) | |
| 4.5 | BioMarin Pharmaceutical Inc. Amended and Restated 2006 Employee Stock Purchase Plan (5) | |
| 4.6 | BioMarin Pharmaceutical Inc. 1997 Amended Stock Plan and Forms of Agreement (6) | |
| 4.7 | Amendment to BioMarin Pharmaceutical Inc. 1997 Stock Plan (7) | |
| 4.8 | Amendment No. 2 to BioMarin Pharmaceutical Inc. 1997 Stock Plan (8) | |
| 4.9 | BioMarin Pharmaceutical Inc. 1998 Director Option Plan (9) | |
| 4.10 | Amendment No. 1 to BioMarin Pharmaceutical Inc. 1998 Director Option Plan (10) | |
| 4.11 | Amendment No. 2 to BioMarin Pharmaceutical Inc. 1998 Director Option Plan (11) | |
| 4.12 | Amendment No. 3 to BioMarin Pharmaceutical Inc. 1998 Director Option Plan (12) | |
| 5.1 | Opinion of Paul, Hastings, Janofsky & Walker LLP * | |
| 23.1 | Consent of Paul, Hastings, Janofsky & Walker LLP (included with 5.1) * | |
| 23.2 | Consent of KPMG LLP, Independent Registered Public Accounting Firm for Bio Marin Pharmaceutical Inc. * | |
| 23.3 | Consent of PricewaterhouseCoopers, LLP, Independent Registered Public Accounting Firm for BioMarin/Genzyme LLC * | |
| 24.1 | Power of Attorney (contained on the signature page) | |
| * | Filed herewith. |
| (1) | Incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 23, 2003 (SEC File No. 000-26727). |
| (2) | Incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 5, 2005 (SEC File No. 000-26727). |
| (3) | Incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 27, 2006 (SEC File No. 000-26727). |
| (4) | Incorporated by reference to Exhibit 99.1 of the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 16, 2006 (SEC File No. 000-26727). |
| (5) | Incorporated by reference to Exhibit 10.3 of the Registrant’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 3, 2006 (SEC File No. 000-26727). |
| (6) | Incorporated by reference to Exhibit 10.2 of the Registrant’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on May 4, 1999 (SEC File No. 333-77701). |
| (7) | Incorporated by reference to Exhibit 99.1 of the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 31, 2002 (SEC File No. 000-26727). |
| (8) | Incorporated by reference to Exhibit 10.1 of the Registrant’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 9, 2004 (SEC File No. 000-26727). |
| (9) | Incorporated by reference to Exhibit 10.3 of the Registrant’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on May 4, 1999 (SEC File No. 333-77701). |
| (10) | Incorporated by reference to Exhibit 10.1 of the Registrant’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 15, 2003 (SEC File No. 000-26727). |
| (11) | Incorporated by reference to Exhibit 10.1 of the Registrant’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2003 (SEC File No. 000-26727). |
| (12) | Incorporated by reference to Exhibit 10.2 of the Registrant’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 9, 2004 (SEC File No. 000-26727). |
Exhibit 5.1
|
August 28, 2006 |
32348.00001 |
Biomarin Pharmaceutical Inc.
105 Digital Drive
Novato, California 94949
| Re: | Registration Statement on Form S-8 |
Ladies and Gentlemen:
We are furnishing this opinion of counsel to Biomarin Pharmaceutical Inc., a Delaware corporation (the “ Company ”), for filing as Exhibit 5.1 to the Registration Statement on Form S-8 (the “ Registration Statement ”) to be filed, on or about August 28, 2006, by the Company with the Securities and Exchange Commission under the Securities Act of 1933, as amended, in connection with the registration of an aggregate of 19,299,775 shares (the “ Shares ”) of the Company’s Common Stock, par value $0.001 per share, under the following plans: (i) 15,000,000 Shares issuable under the Amended and Restated BioMarin Pharmaceutical Inc. 2006 Share Incentive Plan; (ii) 2,500,000 Shares issuable under the BioMarin Pharmaceutical Inc. Amended and Restated 2006 Employee Stock Purchase Plan; (iii) 1,664,775 Shares issuable under the BioMarin Pharmaceutical Inc. 1997 Stock Plan; and (iv) 135,000 Shares issuable under the BioMarin Pharmaceutical Inc. 1998 Director Option Plan (collectively, the “ Plans ”).
We have examined the Plans and exhibits thereto, as applicable, the Company’s certificate of incorporation and bylaws, each as amended to date, and the originals, or copies certified or otherwise identified, of records of corporate action of the Company as furnished to us by the Company, certificates of public officials and of representatives of the Company, and such other instruments and documents as we deemed necessary, as a basis for the opinions hereinafter expressed. In addition, we have made such investigations of law as we have deemed necessary or appropriate as a basis for the opinion set forth herein.
In such examination, we have assumed: (i) the genuineness of all signatures on all documents submitted to us; (ii) the authenticity and completeness of all documents, corporate records, certificates and other instruments submitted to us; (iii) that photocopy, electronic, certified, conformed, facsimile and other copies submitted to us of original documents, corporate records, certificates and other instruments conform to the originals, and that all such originals were authentic and complete; (iv) the legal capacity of all individuals executing documents; (v) the due authorization, execution and delivery of all documents where due authorization, execution and delivery are a prerequisite to the effectiveness thereof; (vi) that the statements contained in the certificates and comparable documents of public officials, officers and representatives of the Company and other
BioMarin Pharmaceutical Inc.
August 28, 2006
Page 2
persons on which we have relied for the purposes of this opinion are true and correct; and (vii) that the officers and directors of the Company have properly exercised their fiduciary duties. As to all questions of fact material to this opinion and as to the materiality of any fact or other matter referred to herein, we have relied (without independent investigation) upon certificates or comparable documents of officers and representatives of the Company.
Our knowledge of the Company and its legal and other affairs is limited by the scope of our engagement, which scope includes the delivery of this letter. We do not represent the Company with respect to all legal matters or issues. The Company may employ other independent counsel and, to our knowledge, handles certain legal matters and issues without the assistance of independent counsel.
Based upon and in reliance on the foregoing, and subject to the limitations and exceptions set forth herein, we are of the opinion that the Shares are duly authorized and, when purchased and paid for as required under the Plans and pursuant to any agreements which accompany a grant under the Plans, will be validly issued, fully paid and nonassessable.
Without limiting any of the other limitations, exceptions and qualifications stated elsewhere herein, we express no opinion with respect to the applicability or effect of the laws of any jurisdiction other than the Delaware General Corporation Law, the applicable provisions of the Delaware Constitution and reported judicial decisions interpreting these laws, as in effect as of the date hereof.
This opinion letter deals only with the specified legal issues expressly addressed herein, and you should not infer any opinion that is not explicitly stated herein from any matter addressed in this letter.
This opinion letter is rendered solely to you in connection with the issuance of the Shares pursuant to the Plans. This opinion letter may not be relied upon by you for any other purpose or delivered to or relied upon by any other person without our prior written consent. This opinion letter speaks as of the date hereof and through the effectiveness of the Registration Statement; however, we assume no obligation to advise you or any other person or entity hereafter with regard to any change in the circumstances or the law that
BioMarin Pharmaceutical Inc.
August 28, 2006
Page 3
may bear on the matters set forth herein after the effectiveness of the Registration Statement even though the change may affect the legal analysis, legal conclusion or other matters in this opinion letter.
We hereby consent to the filing of this opinion of counsel as Exhibit 5.1 to the Registration Statement.
Very truly yours,
/s/ PAUL, HASTINGS, JANOFSKY & WALKER LLP
Exhibit 23.2
CONSENT OF KPMG LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board of Directors
BioMarin Pharmaceutical Inc.:
We consent to the use of our reports dated March 7, 2006, with respect to the consolidated balance sheets of BioMarin Pharmaceutical Inc. and subsidiaries (the Company) as of December 31, 2005 and 2004, and the related consolidated statements of operations, changes in stockholders’ equity (deficit), and cash flows for each of the years in the three-year period ended December 31, 2005, and the related financial statement schedule, management’s assessment of the effectiveness of internal control over financial reporting as of December 31, 2005, and the effectiveness of internal control over financial reporting as of December 31, 2005, incorporated herein by reference.
Our report on the Company’s financial statements as described above was based on our audits and the report of other auditors.
/s/ KPMG LLP
San Francisco, California
August 25, 2006
Exhibit 23.3
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated March 6, 2006 relating to the financial statements of BioMarin/Genzyme LLC, which appear in BioMarin Pharmaceutical Inc.’s Annual Report on Form 10-K for the year ended December 31, 2005.
/s/ PricewaterhouseCoopers LLP
PricewaterhouseCoopers LLP
Boston, MA
August 25, 2006